目的评价聚乙二醇干扰素-α2b对慢性骨髓增殖性肿瘤患者的临床疗效及不良反应。方法回顾性分析107例慢性骨髓增殖性肿瘤病例,其中包括95例原发性血小板增多症(ET),12例真性红细胞增多症(PV),接受聚乙二醇干扰素-α2b治疗12月以上,分析...目的评价聚乙二醇干扰素-α2b对慢性骨髓增殖性肿瘤患者的临床疗效及不良反应。方法回顾性分析107例慢性骨髓增殖性肿瘤病例,其中包括95例原发性血小板增多症(ET),12例真性红细胞增多症(PV),接受聚乙二醇干扰素-α2b治疗12月以上,分析其临床数据,评价疗效和不良反应。结果接受聚乙二醇干扰素-α2b治疗后,ET及PV患者均获得较高的血液学缓解率(P<0.05),ET与PV治疗组间缓解率差异无统计学意义(0.86 vs 0.78,P>0.05),脾脏长厚径(脾脏指数)下降13.5%(95%CI:8.5%~18.5%),获得血液学缓解的患者MPN10评分下降较为显著(P<0.01)。PV患者JAK2V617F等位基因突变负荷中位值由67.23%(49.6%~84.86%)下降至19.7%(0.57%~74.6%)(P<0.05);ET患者JAK2V617F突变定量阳由48.97%(0.45%~74.24%)下降至22.1%(0.33%~65.42%)(P<0.05)。ET和PV患者观察到轻微不良反应(1-2级),差异无统计学意义。治疗期间血栓事件发生率为2.8%。未观察到严重不良反应。结论聚乙二醇干扰素-α2b治疗PV和ET获得较高的外周血细胞缓解率,具有缩脾疗效,并降低JAK2V617F基因突变负荷,不良反应轻微,多数患者可耐受。展开更多
BACKGROUND Nucleos(t)ide analog(NA)has shown limited effectiveness against hepatitis B surface antigen(HBsAg)clearance in chronic hepatitis B(CHB)patients.AIM To evaluate the efficacy and safety of add-on peginterfero...BACKGROUND Nucleos(t)ide analog(NA)has shown limited effectiveness against hepatitis B surface antigen(HBsAg)clearance in chronic hepatitis B(CHB)patients.AIM To evaluate the efficacy and safety of add-on peginterferonα-2a(peg-IFNα-2a)to an ongoing NA regimen in CHB patients.METHODS In this observational study,195 CHB patients with HBsAg≤1500 IU/m L,hepatitis B e antigen(HBeAg)-negative(including HBeAg-negative patients or HBeAg-positive patients who achieved HBeAg-negative after antiviral treatment with NA)and hepatitis B virus-deoxyribonucleic acid<1.0×10^2 IU/mL after over 1 year of NA therapy were enrolled between November 2015 and December2018 at the Second Affiliated Hospital of Xi'an Jiaotong University,China.Patients were given the choice between receiving either peg-IFNα-2a add-on therapy to an ongoing NA regimen(add-on group,n=91)or continuous NA monotherapy(monotherapy group,n=104)after being informed of the benefits and risks of the peg-IFNα-2a therapy.Total therapy duration of peg-IFNα-2a was 48 wk.All patients were followed-up to week 72(24 wk after discontinuation of peg-IFNα-2a).The primary endpoint was the proportion of patients with HBsAg clearance at week 72.RESULTS Demographic and baseline characteristics were comparable between the two groups.Intention-to-treatment analysis showed that the HBsAg clearance rate in the add-on group and monotherapy group was 37.4%(34/91)and 1.9%(2/104)at week 72,respectively.The HBsAg seroconversion rate in the add-on group was 29.7%(27/91)at week 72,and no patient in the monotherapy group achieved HBsAg seroconversion at week 72.The HBsAg clearance and seroconversion rates in the add-on group were significantly higher than in the monotherapy group at week 72(P<0.001).Younger patients,lower baseline HBsAg concentration,lower HBsAg concentrations at weeks 12 and 24,greater HBsAg decline from baseline to weeks 12 and 24 and the alanine aminotransferase≥2×upper limit of normal during the first 12 wk of therapy were strong predictors of HBsAg clearance i展开更多
目的评价恩替卡韦联合聚乙二醇干扰素α-2a治疗慢性乙型病毒性肝炎(乙肝)的临床疗效及安全性。方法将80例慢性乙肝患者随机分为对照组40例和试验组40例。对照组皮下注射聚乙二醇干扰素α-2a 0.5 m L,每周一次;试验组在对照组的基础上,...目的评价恩替卡韦联合聚乙二醇干扰素α-2a治疗慢性乙型病毒性肝炎(乙肝)的临床疗效及安全性。方法将80例慢性乙肝患者随机分为对照组40例和试验组40例。对照组皮下注射聚乙二醇干扰素α-2a 0.5 m L,每周一次;试验组在对照组的基础上,加用口服恩替卡韦0.5 mg,每天一次。2组患者一个疗程均为一个月,均治疗12个疗程。分别在治疗3,6,12个月和治疗后6个月,检测并分析2组患者乙肝病毒(HBV)DNA阴转率和谷丙转氨酶复常率的情况。比较治疗后2组患者的临床疗效以及不良反应发生率。结果治疗后,试验组的总有效率92.50%显著高于对照组67.50%(P<0.05)。治疗3,6,12个月以及治疗后6个月,试验组的HBV DNA阴转率和谷丙转氨酶复常率均明显高于对照组(P<0.05)。2组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论恩替卡韦联合聚乙二醇干扰素α-2a治疗慢性乙肝的临床疗效显著,安全性较好。展开更多
文摘目的评价聚乙二醇干扰素-α2b对慢性骨髓增殖性肿瘤患者的临床疗效及不良反应。方法回顾性分析107例慢性骨髓增殖性肿瘤病例,其中包括95例原发性血小板增多症(ET),12例真性红细胞增多症(PV),接受聚乙二醇干扰素-α2b治疗12月以上,分析其临床数据,评价疗效和不良反应。结果接受聚乙二醇干扰素-α2b治疗后,ET及PV患者均获得较高的血液学缓解率(P<0.05),ET与PV治疗组间缓解率差异无统计学意义(0.86 vs 0.78,P>0.05),脾脏长厚径(脾脏指数)下降13.5%(95%CI:8.5%~18.5%),获得血液学缓解的患者MPN10评分下降较为显著(P<0.01)。PV患者JAK2V617F等位基因突变负荷中位值由67.23%(49.6%~84.86%)下降至19.7%(0.57%~74.6%)(P<0.05);ET患者JAK2V617F突变定量阳由48.97%(0.45%~74.24%)下降至22.1%(0.33%~65.42%)(P<0.05)。ET和PV患者观察到轻微不良反应(1-2级),差异无统计学意义。治疗期间血栓事件发生率为2.8%。未观察到严重不良反应。结论聚乙二醇干扰素-α2b治疗PV和ET获得较高的外周血细胞缓解率,具有缩脾疗效,并降低JAK2V617F基因突变负荷,不良反应轻微,多数患者可耐受。
基金the National Natural Science Foundation of China,No.31500650。
文摘BACKGROUND Nucleos(t)ide analog(NA)has shown limited effectiveness against hepatitis B surface antigen(HBsAg)clearance in chronic hepatitis B(CHB)patients.AIM To evaluate the efficacy and safety of add-on peginterferonα-2a(peg-IFNα-2a)to an ongoing NA regimen in CHB patients.METHODS In this observational study,195 CHB patients with HBsAg≤1500 IU/m L,hepatitis B e antigen(HBeAg)-negative(including HBeAg-negative patients or HBeAg-positive patients who achieved HBeAg-negative after antiviral treatment with NA)and hepatitis B virus-deoxyribonucleic acid<1.0×10^2 IU/mL after over 1 year of NA therapy were enrolled between November 2015 and December2018 at the Second Affiliated Hospital of Xi'an Jiaotong University,China.Patients were given the choice between receiving either peg-IFNα-2a add-on therapy to an ongoing NA regimen(add-on group,n=91)or continuous NA monotherapy(monotherapy group,n=104)after being informed of the benefits and risks of the peg-IFNα-2a therapy.Total therapy duration of peg-IFNα-2a was 48 wk.All patients were followed-up to week 72(24 wk after discontinuation of peg-IFNα-2a).The primary endpoint was the proportion of patients with HBsAg clearance at week 72.RESULTS Demographic and baseline characteristics were comparable between the two groups.Intention-to-treatment analysis showed that the HBsAg clearance rate in the add-on group and monotherapy group was 37.4%(34/91)and 1.9%(2/104)at week 72,respectively.The HBsAg seroconversion rate in the add-on group was 29.7%(27/91)at week 72,and no patient in the monotherapy group achieved HBsAg seroconversion at week 72.The HBsAg clearance and seroconversion rates in the add-on group were significantly higher than in the monotherapy group at week 72(P<0.001).Younger patients,lower baseline HBsAg concentration,lower HBsAg concentrations at weeks 12 and 24,greater HBsAg decline from baseline to weeks 12 and 24 and the alanine aminotransferase≥2×upper limit of normal during the first 12 wk of therapy were strong predictors of HBsAg clearance i
